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We examined the effects of a newly synthesized gastrin receptor antagonist,
AG-041R, on the growth of enterochromaffin-like (ECL) carcinoid tumors in
Mastomys natalensis both in vitro and in vivo. AG-041R was as potent as the
well known gastrin antagonist L365,260 in inhibiting not only the gastrin-
induced release ofhistamine frombut also histidine decarboxylase (HDC) gene
expression in the ECL carcinoid tumor cells. AG-041R also inhibited gastrin-
induced DNA synthesis and c-fos gene expression in the tumor cells.
Furthermore, AG-041R significantly inhibited the growth of the transplanted
Mastomys ECL carcinoid tumors in vivo. From these data, it is concluded that
endogenous gastrin is involved in the growth of ECL carcinoid tumors in
Mastomys natalensis. Moreover, AG-041R is shown to have a potential as an
anti-neoplastic agent for ECL carcinoid tumor ofthe stomach.
INTRODUCTION
In addition to stimulating histamine release along with the resulting acid secretion
from parietal cells, gastrin has a trophic effects on enterochromaffin-like (ECL)e cells in
the fundic mucosa. Indeed, it is well known that patients with hypergastrinemia such as
type A gastritis or Zollinger-Ellison syndrome with multiple endocrine neoplasia (MEN)
type I have a tendency to develop ECLcarcinoid tumor ofthe stomach [1-5]. Forexample,
in our series of patients, 22 out of 25 patients with gastric carcinoid tumors had hyper-
gastrinemia, whereas only one patient with colon carcinoid tumor had hypergastrinemia
(Table 1). Moreover, we have identified significant expression ofgastrin receptor mRNAs
in all ofthe five gastric carcinoid tumors with hypergastrinemia tested to date (Figure 1).
Although most carcinoid tumors of the stomach are quite indolent and tend to remain
localized to their site oforigin for extremely long periods [4, 5], several cases have been
reported to have metastasized to local lymph nodes [4, 5]. Thus, it is possible that gastrin
receptor antagonists may be more important as anti-neoplastic agents forgastric carcinoid
tumors than as anti-acid agents.
In the present study, therefore, we examined the effects of a newly developed gastrin
receptorantagonist,AG-041R, on the growth ofECLcarcinoid tumors inMastomys natal-
ensis both in vitro and in vivo.
aTo whom all correspondence should beaddressed: Prof. Tsutomu Chiba, M.D., Ph.D., Division of
Gastroenterology and Hepatology, Department of Internal Medicine, Postgraduate School of
Medicine, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606, Japan. Tel.: 81-75-751-4302; Fax: 81-
75-751-4303.
eAbbreviations: ECL, enterochromaffin-like; HDC, histidine decarboxylase; MEN, multiple
endocrine neoplasia; DMSO, dimethylsulfoxide; CMC, carboxymethylcellose.
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MATERIALS AND METHODS
Drugs
AG-041R is a recently discovered potent nonpeptide and nonbenozodiazepine deriv-
ative CCKB/gastrin receptor antagonist with low affinity for CCKA receptors (Table 2).
AG-041R [3R-1(2,2-Diethoxyethyl)-3-((4-methylphenyl)aminocarbonylmethyl)-3-((4-
methylphenyl)ureido)-indoline-2-one] was synthesized by Chugai Pharmaceutical Co.
(Tokyo, Japan) (Figure 2). AG-041R was dissolved with dimethylsulfoxide (DMSO) for
the in vitro study and was suspended in 0.3 percent carboxymethylcellose (CMC) for the
in vivo study.
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Figure 1. Gastrin receptor gene expression in human and Mastomys ECL carcinoid tumor of
the stomach. ECC12 is a gastric endocrine cell line [10]. The size of human gastrin receptors is
slightly larger than those ofMastomys and of rats.
Table 1. Carcinoid tumor in the gastrointestinal tract.
Hyper-gastrinemia
(+) (-) Unknown
Colon carcinoid 1 28 10
Gastric carcinoid 22* 3 4
Endocrine Cell 2 1 1
Cancer ofthe stomach
*One case is ZE syndrome with MEN type-I, and the other 21 cases are type Agastritis. The data
were obtained in Kobe, Japan between 1989 and 1996.
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Figure 2. Chemical structure ofAG-041R.
L-365,260(providedbyMerck&Sharp, Philadelphia, PA)wasdissolvedwithDMSO, and
Lansoprazole (LPZ;TakedaPharmaceutical CO.,Tokyo) was suspendedin0.3percentCMC.
Preparation ofthe ECLcarcinoid tumorcells and its cellmembranes in Mastomys natalensis
A primary ECL carcinoid tumor arose in the glandular stomach of a two-year-old
Mastomys natalensis female. The tumor was serially transplanted into the thigh muscles
of one- to two-month-old male Mastomys [6] and was then used in this experiment. The
transplanted tumors from Mastomys were minced and then dispersed with 0.4 mg/ml col-
lagenase (type I) (Sigma St. Louis, MO) and 4 mg/ml dispase (Sanko Chemicals, Tokyo,
Japan). After washing twice, the dispersed cells were suspended in Krebs-Ringer
Bicarbonate buffer (pH 7.4) with 10 mM HEPES, 1 mg/ml BSA and 2.5 mM D-glucose.
A crude membrane preparation of the ECL tumor was obtained as described previ-
ously [7]. The tumor tissue was minced and homogenized with a glass homogenizer in
HEPES buffer (10 mM, pH 7.4) containing 1 mg/ml bacitracin. After filtration through
surgical gauze, the homogenate was centrifuged at 1,000 x g for 2 min. The supernatant
was then recentrifuged at 20,000 x g for 15 min. After washing twice, the resulting pellet
was resuspended in 10 mM HEPES buffer (pH 5.5) containing 120 mM NaCl, 4.7 mM
KCI, 5 mM MgCl2, 1 mM ethylene glycol-bis (f-aminoethyl ether)-N,N,N',N'-tetraacetic
acid, 1 mg/ml bacitracin, and 5 mg/ml BSA.
125I-human gastrin I binding experiment
Binding studies were carried out in a volume of 500 ml 10 mM HEPES buffer (pH
7.4) containing 25 pM 125I-gastrin and 300 mg crude membrane protein with or without
various unlabeled agents. Following incubation at 24°C for 60 min, bound and free hor-
mone fractions were separated by centrifugation, andradioactivity remaining bound to the
pellets was counted [7].
Measurement ofhistamine release
After 10 min of preincubation at 37°C in a shaking bath, the dispersed cells were
incubated for 30 min with or without various test agents in Krebs'-Ringer bicarbonate
buffer (pH 7.4) with 10 mM HEPES, 1 mg/ml BSA, 2.5 mM D-glucose and 0.1 mM
IBMX (106 cells/ml) [8]. The reactions were then stopped by adding 4 ml ice-cold incu-
bation medium; after centrifugation, the supematant was stored at -30°C until assay. The
histamine concentration in each sample was directly measured by an RIA kit
(Immunotech S.A., Marseilles, France).
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Figure 3. Inhibition of1251-human gastrin I binding to the ECLcarcinoid tumormembrane of
Mastomys by gastrin receptor antagonists. The data are means from triplicate samples, and are
expressed as percentages of maximal specific binding in the presence of 10- M CCK8.
Representative data from three separate experiments are shown.
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Figure 4. Effect ofgastrin receptorantagonists on the gastrin (10-8M)-induced increase ofhis-
tamine release from the ECLcarcinoid tumorcells ofMastomys. The values are means fromtrip-
licate samples and are expressed as percentages of histamine release induced by gastrin (10-8 M)
alone.
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Cell incubation and RNA blot analysis
Dispersed cells were incubated with or without gastrin (10-8 M) in the presence or
absence ofAG-041R (10-7 M) for lh. After washing, total cellular RNA was extracted as
described [9]. Samples were electrophoresed on a 1 percent agarose/formaldehyde gel,
and transferred to nitrocellulose filters. Filters were hybridized at 42°C with 32P-labeled
HDC or c-fos cDNA probes. After 16h hybridyzation, filters were washed twice for 20
min in 2 x SSC, 0.1 percent SDS at 50°C, and autoradiographed.
3H-thymidine incorporation
Dispersed cells were incubated under serum starved conditions for 5h. The cells were
then incubated in 24-well plates in the presence or absence of gastrin (10-8 M) with or
without various concentrations ofAG-041R or L365,260 for 1Oh followed by a further 5h
incubation with methyl-3H-thymidine (1 mci/ml) (Amersham, Buckinghamshier, UK).
Theradioactivity ofthe incorporated 3H-thymidine in 6percenttrichloroacetic acid-insoluble
precipitates was counted after lysing in 1 percent SDS/10 mM NaOH.
In vivo growth experiments
Dispersed tumor cells (107 each) were transplanted into the thigh muscles of a one
month-old male Mastomys. The Mastomys animals were then divided into four groups (8
animals per group). One group was used as control. The second group received daily non-
parentheral administration of LPZ at a dose of 10 mg/kg for one month. The third group
was given AG-041R (30 mg/kg) orally for one month. The fourth group received con-
comitant administration ofAG-041R (30 mg/kg) and LPZ (10 mg/kg). One month after
the start of the administration of the drugs, the animals were anesthetized, the tumors in
the thigh muscles were taken out, and their diameters measured.
C,
C, C,
Figure 5. Effect ofAG-041R (10-7 M) on the increase of histidine decarboxylase (HDC) gene
expression induced by gastrin(1O-8 M).
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RESULTS AND DISCUSSION
AG-041R displaced the specific binding of 125I-human gastrin I to the ECL carcinoid
tumor cell membranes in Mastomys in a dose-despendent fashion with a potency similar
to L365,260 (Figure 3). This binding inhibition by AG-041R was associated with a dose-
dependent inhibition ofthe histamine release from these carcinoid tumor cells induced by
gastrin, again with a similar potency to L365,260 (Figure 4). In agreement with these data,
AG-041R inhibited the gastrin-induced increase ofHDC gene expression in the carcinoid
tumor cells (Figure 5).
AG-041R clearly suppressed the gastrin-induced enhancement of c-fos gene expres-
sion (Figure 6). Moreover, AG-041R dose-dependently inhibited the gastrin-induced
SP& <@C,
Figure 6. Effect ofAG-041R (10-7 M) on the increase ofc-fos gene expression induced by gas-
trin (10-8 M).
Table 2. IC50 ofAG-041R on the bindings of1251-Gastrin to guinea pig isolated gastric glands
and 1251-CCK8 to rat pancreatic acinar membranes.
IC50
CCK-B CCK-A Ratio
Compound receptors receptors (CCKA/CCKB)
AG-041R 1.11 620.0 558.6
Y M022 1.02 19.7 19.3
L 365,260 2.19 949.0 433.3
L 364,718 338.0 0.45 0.001
Human gastrin 9.61 356.0 37.0
CCK-8 1.29 0.21 0.16
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Figure 7. Effects ofgastrin antagonists on the gastrin (10-8 M)-induced increase of3H-thymi-
dine incorporation into the ECL carcinoid tumor cells ofMastomys . The data are means of
quadruplicate samples, and are expressed as percentages of maximal incorporation induced
by gastrin (10-8 M).
LPZ
TI
AG-041 R LPZ+AG-041 R
Figure 8. Effects ofAG-041R on the growth ofMastomys ECL carcinoid tumors transplanted
to the thigh muscles ofmale Mastomys. The data are the diameter of the transplanted tumors one
month after the transplantation and are expressed as means ± SE from eight animals.
E
E
0
-1
z
0
0 0. a.
0
0 z
z
5
I
C- x
V.
85-
80
800-
600-
E
E E
w
N
c') 400-
0
200-
0-
TI
Co.
253254 Chiba et al.: Gastrin receptor antagonist and ECL carcinoid tumorgrowth
increase of3H-thymidine incorporation into the tumor cells (Figure 7). These data clearly
indicatethatAG-041R is apotentantagonist ofgastrinreceptors onMastomys ECLcarcinoid
tumor cells, inhibiting not only histamine release but also cell growth.
Therefore, we next examined the effects of AG-041R on the growth of Mastomys
ECL carcinoid tumors in vivo. As shown in Figure 8, LPZ significantly enhanced the
growth ofthe transplanted ECLcarcinoid tumors (p < .01 vs control). AG-041R significantly
reduced this LPZ- enhanced tumorgrowth. However, the mostnoteworthy finding was that
AG-041R significantly inhibited not only the LPZ (p < .01 vs LPZ alone) -induced but
also the spontaneous growth ofthe transplanted ECLcarcinoid tumors (p < .01 vs control).
Since Mastomys exhibits normal level of serum gastrin (data not shown), this finding
strongly suggests that circulating gastrin, even at physiological concentrations, plays a
role in the development ofECL carcinoid tumors in Mastomys natalensis.
It should be noted that some patients with gastric carcinoid tumors do nothave hyper-
gastrinemia [4, 5], and the growth of carcinoid tumors in those patients is believed to be
independent of their serum gastrin levels. In case of Mastomys, it is considered that in
addition togastrincertain genetic factors play arole inthe development oftheECLcarcinoid
tumors. Yet even under such conditions, serum gastrin at physiological concentrations
appears to have atrophic action on the growth ofthe ECLcarcinoid tumors. Thus, whether
or not the growth of sporadic gastric carcinoid tumors without concomitant hypergas-
trinemia inhumans isdependentonphysiological levels ofgastrin inthebloodis aninteresting
question thatremains tobe elucidated. In this regard, it is worth noting thatgastric carcinoid
tumors without hypergastrinemia usually have a worse prognosis than those with hyper-
gastrinemia [4, 5]. Thus, specific antagonists for gastrin receptors like AG-041R might
also be useful for the treatment of the carcinoid tumors of the stomach with or without
hypergastrinemia.
In conclusion, the present study clearly showed that gastrin is involved in the growth
oftheECLcarcinoidtumorofMastomys. Moreover,AG-041R maybeuseful forthetreatment
ofECL carcinoid tumors ofthe stomach.
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